Both hypertension and hyperuricemia are closely associated with the morbidity and mortality of heart failure. This study was designed to evaluate the influences of long-term xanthine oxidase inhibitor (febuxostat) prescription on left ventricular hypertrophy (LVH), left ventricular (LV) diastolic function, and new-onset heart failure with preserved ejection fraction (HFpEF) in these patients. Using a propensity score matching of 1:2 ratio, this retrospective claims database study compared febuxosatat prescription (n = 96) and non-urate-lowering therapy (n = 192) in patients with hypertensive left ventricular hypertrophy (LVH) and asymptomatic hyperuricemia. With a follow-up of 36 months, febuxostat significantly decreased the level of serum uric acid as well as generated more prominent improvement in LVH and LV diastolic function. Besides, the new-onset symptomatic HFpEF occurred in 2 of 96 patients in febuxostat group and 13 of 192 patients in non-urate-lowering group (P = 0.091). No increased risk for major adverse cardiovascular events in patients prescribed with febuxostat was noted. In conclusion, long-term febuxostat exposure was associated with protective effects in terms of LVH or LV diastolic dysfunction in patients with hypertensive LVH and asymptomatic hyperuricemia. Febuxostat also displayed a trend for reduced risk of new-onset HFpEF in this population.

中文翻译：

---

高血压和无症状高尿酸血症患者长期服用非布司他处方与心力衰竭进展与射血分数保留之间的关系。

高血压和高尿酸血症均与心力衰竭的发病率和死亡率密切相关。本研究旨在评估长期使用黄嘌呤氧化酶抑制剂（非布索坦）处方对这些患者左心室肥厚（LVH），左心室（LV）舒张功能和新发性心力衰竭伴射血分数（HFpEF）的影响。耐心。该回顾性索赔数据库研究使用倾向得分匹配为1：2的比例，比较了高血压左心室肥厚（LVH）和无症状性高尿酸血症患者的非布索他特处方（n = 96）和非降尿酸疗法（n = 192）。经过36个月的随访，非布索坦显着降低了血清尿酸水平，并在LVH和LV舒张功能方面产生了更为显着的改善。除了，非布索坦组96例患者中有2例发生新的症状性HFpEF，非尿酸降低组192例中有13例发生新的症状（P = 0.091）。服用非布索坦的患者未出现重大不良心血管事件的风险增加。总之，长期服用非布索坦对高血压LVH和无症状性高尿酸血症患者的LVH或LV舒张功能障碍具有保护作用。非布索坦还显示出该人群新发HFpEF风险降低的趋势。长期服用非布索坦与高血压，无症状性高尿酸血症的LVH或LV舒张功能障碍有关。非布索坦还显示出该人群新发HFpEF风险降低的趋势。长期服用非布索坦与高血压，无症状性高尿酸血症的LVH或LV舒张功能障碍有关。非布索坦还显示出该人群新发HFpEF风险降低的趋势。